Overexpression of O-polysaccharide chain length regulators in Gram-negative bacteria using the Wzx-/Wzy-dependent pathway enhances production of defined modal length O-polysaccharide polymers for use as haptens in glycoconjugate vaccines

N. Hegerle¹,², J. Bose¹,², G. Ramachandran¹,², J.E. Galen¹,², M.M. Levine¹,²,³, R. Simon¹,² and S.M. Tennant¹,²

1 Center for Vaccine Development and Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD, USA
2 Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
3 Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA

Keywords
glycoconjugate, haptens, LPS (Lipopolysaccharide), O-polysaccharide, pseudomonas, salmonella, vaccines.

Abstract
Aims: O-polysaccharide (OPS) molecules are protective antigens for several bacterial pathogens, and have broad utility as components of glycoconjugate vaccines. Variability in the OPS chain length is one obstacle towards further development of these vaccines. Introduction of sizing steps during purification of OPS molecules of suboptimal or of mixed lengths introduces additional costs and complexity while decreasing the final yield. The overall goal of this study was to demonstrate the utility of engineering Gram-negative bacteria to produce homogenous O-polysaccharide populations that can be used as the basis of carbohydrate vaccines by overexpressing O-polysaccharide chain length regulators of the Wzx-/Wzy-dependent pathway.

Method and Results: The O-polysaccharide chain length regulators wzzB and fepE from Salmonella Typhimurium I77 and wzz2 from Pseudomonas aeruginosa PAO1 were cloned and expressed in the homologous organism or in other Gram-negative bacteria. Overexpression of these Wzz proteins in the homologous organism significantly increased the proportion of long or very long chain O-polysaccharides. The same observation was made when wzzB was overexpressed in Salmonella Paratyphi A and Shigella flexneri, and wzz2 was overexpressed in two other strains of P. aeruginosa.

Conclusions: Overexpression of Wzz proteins in Gram-negative bacteria using the Wzx/Wzy-dependant pathway for lipopolysaccharide synthesis provides a genetic method to increase the production of an O-polysaccharide population of a defined size.

Significance and Impact of the Study: The methods presented herein represent a cost-effective and improved strategy for isolating preferred OPS vaccine haptens, and could facilitate the further use of O-polysaccharides in glycoconjugate vaccine development.

Introduction
Lipopolysaccharides (LPS) are the main constituents of the Gram-negative bacterial (GNB) outer membrane. The basic structure of LPS is comprised of three distinct units. The lipid A serves as a membrane anchor and possesses endotoxic properties. The core polysaccharide is covalently attached to lipid A and is mostly conserved within
individual bacterial species. The final component is the O-polysaccharide (OPS) that extends from the core and is a variable polymer of repeating saccharide units for which the chemical structure defines the associated bacterial serogroup (Erridge et al. 2002). While most GNB (e.g. *Salmonella enterica*, *Shigella flexneri*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*) possess OPS, some GNB (e.g. *Bordetella pertussis*, *Neisseria meningitidis*, *Haemophilus influenzae*) produce lipo-oligosaccharide or LOS, that is short and characterized by only a few saccharide repeats.

Unlike the conserved core region, the OPS can be highly variable between bacteria of the same species and infection with a GNB pathogen can induce production of highly specific anti-OPS antibodies that recognize the abundant surface-associated OPS of GNB human pathogens (e.g. *K. pneumoniae* (Podschun and Ullmann 1998), *S. enterica* (Wattiau et al. 2011), *P. aeruginosa* (Al-Dujaili and Harris 1974)). Antibodies specific for OPS have shown promise as vaccine antigens for several bacterial pathogens, whereby they have protected against challenge with the homologous pathogen in preclinical animal models (Svenson and Lindberg 1981; Watson et al. 1992; Simon et al. 2011). Glycoconjugate vaccines of *S. Paratyphi* A OPS with tetanus toxoid (TT) elicited bactericidal antibodies in human trials in Vietnam (Konadu et al. 2000). A *Shigella sonnei* core and OPS (COPS) glycoconjugate with recombinant *P. aeruginosa* exo-protein A demonstrated efficacy against clinical disease due to the homologous OPS expressing pathogen in a double-blind vaccine-controlled randomized clinical trial for efficacy conducted among Israeli army recruits (Cohen et al. 2011). However, despite these promising studies there is currently no licensed OPS-based human vaccine.

As isolated antigens, polysaccharides are generally poorly immunogenic and usually considered T-independent antigens that fail to activate maturation of memory B cells and antibody class switching (Finco and Rappuoli 2014). Chemical linkage, or conjugation, of the OPS to a carrier protein has been shown to improve immunogenicity (Campbell et al. 1996; Simon et al. 2011) by engagement of carrier protein-specific T cells, and enabling the presentation of the OPS-peptide on MHCII for engagement of polysaccharide-specific CD4+ T-helper cells (Avci et al. 2011). Variability in O polymer size expressed by the bacteria used as the source of OPS antigen represents a practical challenge, however, for vaccine development. The size of the polysaccharide hapten can play an important role in the immune response to carbohydrate vaccines (Kubler-Kielb et al. 2010; Zhang et al. 2013; Broker et al. 2016). Individual bacterial strains may also express a wide range of OPS sizes that, in some instances, may not include the desired target size for vaccine development.

Two major pathways have been described for the synthesis and export of GNB polysaccharides: the Wzx-/Wzy-dependant pathway (Islam and Lam 2014) (e.g. *S. enterica*, *S. flexneri* and *P. aeruginosa*) and the ABC transporter-dependent pathway (e.g. *Klebsiella pneumoniae* and some *Escherichia coli*) (Greenfield and Whitfield 2012). For OPSs synthesized through the Wzx-/Wzy-dependent pathway, the Wzz family proteins are membrane-associated O antigen chain length regulators expressed in the periplasm of GNBs that control the modal number of OPS repeats polymerized by the Wzy protein. Some species encode several different Wzz proteins, each producing a unique OPS modal length (Daniels et al. 2002; Murray et al. 2003). In *S. Typhimurium*, WzzB controls the biosynthesis of long-chain OPS with average chain lengths of 16–35 repeat units of polysaccharide monomer while FepE controls the biosynthesis of very long OPS with average chain lengths of >100 repeat units (Murray et al. 2003). In *P. aeruginosa*, Wzz1 controls the synthesis of two distinct OPS population with modal OPS lengths of 12–16 and 22–30 repeat units while Wzz2 is responsible for the biosynthesis of long-chain O-polysaccharide with average chain lengths of 40–50 repeat units of polysaccharide monomer (Daniels et al. 2002). The endogenous expression of these OPS biosynthesis proteins can be subject to control by growth phase and environmental conditions (Carter et al. 2007; Bravo et al. 2008).

Murray et al. demonstrated that, in *S. Typhimurium*, complementation of wzz mutants with homologous plasmid-encoded wzz genes leads to the synthesis of OPS incorporating the number of repeat units governed by the heterologous expressed Wzz protein (Murray et al. 2003). The overexpression of selected wzz genes in wild-type strains should thus enable a bias for OPS size towards a population mainly comprising polysaccharides of a modal length defined by the overexpressed Wzz. In this article, we report the cloning of Wzz proteins from *S. Typhimurium* and *P. aeruginosa* and describe the impact of Wzz overexpression on the size distribution of the OPS population in homologous or heterologous strains using the Wzx-/Wzy-dependent pathway for OPS synthesis.

**Materials and methods**

**Bacterial strains, medium, and growth**

The strains used in this study are described in Table 1. All strains were maintained on HS bacteriological media (5 g l⁻¹ sodium chloride, 10 g l⁻¹ soytone [Teknova, Hollister, CA, USA], 5 g l⁻¹ Hy-yest [Kerry, Beloit, WI, USA]) at 37°C. Growth medium for all gBNAB mutants was supplemented with guanine (0.001% w/v). Kanamycin or carbenicillin was added at a final concentration of 50 μg ml⁻¹ for pSEC10 and pSE280 maintenance, respectively, in *Salmonella* spp. and *Shigella* spp. Carbenicillin
was added at a final concentration of 250 µg ml⁻¹ for pUCP19 maintenance in *P. aeruginosa* strains PAO1, IATS O6 and IATS O11. Isopropyl β-D-1-thiogalactopyranoside (IPTG; Teknova, Hollister, CA, USA) was added at 0.1 mol l⁻¹ final concentration for induction of *wzz2* overexpression in *P. aeruginosa* strains.

**DNA techniques**

**DNA amplification**
The primers used in this study are listed in Table 2. Amplification of *wzzB* and *fepE* from *S. Typhimurium* I77 and *wzz2* from *P. aeruginosa* PAO1 was conducted in 50 µl final volume using Vent® DNA polymerase (New England Biolabs, Ipswich, MA, USA) according to the manufacturer’s protocol. PCR products were purified using a QIAGEN Mini-preps DNA purification kit (Qiagen, Germantown, MD, USA) according to the manufacturer’s protocol.

**Plasmid DNA preparation**
Plasmids were purified using the Wizard® Plus SV Mini-preps DNA purification kit (Promega, Madison, WI, USA).

**DNA digestion and ligation**
Purified PCR products and plasmids were digested with the appropriate restriction endonucleases (New England Biolabs, MA, USA) and ligated with T4 DNA ligase (New-England Biolabs, Ipswich, MA, USA). All plasmids were verified by sequencing (Genewiz, South Plainfield, NJ, USA) for the correct insertion of *wzzB, fepE* and *wzz2*.

**Genetic engineering of strains that overexpress *wzzB* and *fepE***

**Expression of *wzzB* from a low copy number plasmid**
*wzzB* from *S. Typhimurium* I77 was first cloned into the high copy number, ampicillin-resistant plasmid pSE280. The 1-kbp PCR product was digested with BamHI and PstI, ligated to the similarly digested pSE280 (3.9 kbp) and electroporated into *E. coli* DH5alpha. *wzzB* from pSE280-*wzzB* was then cloned into pSEC10 (7.2 kbp), a low copy number expression plasmid which encodes resistance to kanamycin (Stokes et al. 2007). A 984-bp fragment encoding *wzzB* was obtained by digesting pSE280-*wzzB* with BamHI and NheI and was ligated to the similarly digested pSEC10. The resultant pSEC10-*wzzB* plasmid was transformed into *S. Paratyphi* A CVD 1902, *S. Typhimurium* CVD 1925 and *S. flexneri* CVD 1208S.

**Expression of *fepE* from pSEC10**
*fepE* amplified from *S. Typhimurium* I77 was digested with BamHI and NheI and inserted as a 1.1-kbp fragment into the similarly digested pSEC10 plasmid. The 748-bp pSEC10-*fepE* plasmid was subsequently transformed into *S. Paratyphi* A CVD 1902.

**Expression of *wzz2* from pUCP19**
*wzz2* was amplified from *P. aeruginosa* PAO1 and was cloned into the ampicillin-resistant low copy number expression shuttle vector pUCP19 (4.6 kbp) (Schweizer 1991). The BamHI and EcoRI-digested 1.3-kbp PCR product was ligated to the similarly digested pUCP19 vector and the 5872-bp pUCP19-*wzz2* plasmid was transformed into *P. aeruginosa* PAO1, IATS O6 and IATS O10.

**LPS isolation and visualization**
Overnight bacterial cultures of *S. Typhimurium* CVD 1925, *S. Paratyphi* A CVD 1902 and *S. flexneri* CVD 1208S were adjusted to an OD₆₀₀ nm of 1 and then 2 ml of culture was centrifuged at 15 000 × g for 2 min at 4°C. The supernatant was removed and the bacterial pellet was resuspended in 100 µl lysis buffer (0.1 M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 4% 2-mercaptoethanol). The sample was boiled at 100°C for 10 min to lyse the cells. Proteins were digested by adding 25 µg Proteinase K and incubating the sample for one h

---

**Table 1** Bacterial strains used in this study

| Bacterial strains name | Mutations | Characteristics | References |
|------------------------|-----------|-----------------|------------|
| *Salmonella* Paratyphi A CVD 1902 | ΔguaBA Δcpx | Candidate live attenuated vaccine, serogroup A (O:2) | ClinicalTrials.gov NCT01129453 |
| *Salmonella* Typhimurium CVD 1925 | ΔguaBA ΔcplP ΔfliD ΔfliB | Reagent strain for OPS purification for conjugate vaccine, serogroup B (O:4) | (Tennant et al. 2011) |
| *Salmonella* flexneri CVD 1208S | ΔguaBA Δset | Candidate live attenuated vaccine, serogroup 2a | (Kotloff et al. 2007) |
| *Pseudomonas aeruginosa* PAO1 | None O5 | | (Holloway 1969) |
| *Pseudomonas aeruginosa* IATS O6 | None O6 | | (Lam et al. 1987) |
| *Pseudomonas aeruginosa* IATS O10 | None O10 | | (Lam et al. 1987) |
Overexpression of \textit{wzzB} and \textit{fepE} in the homologous organism

Overexpression of \textit{S. Typhimurium} \textit{wzzB} from pSEC10-\textit{wzzB} in \textit{S. Typhimurium} CVD 1925 resulted in a significant increase in the proportion of long OPS and concomitant decrease in the proportion of short and medium length OPS (Fig. 2) compared to \textit{S. Typhimurium} CVD 1925. Similar results were observed when \textit{wzzB} was overexpressed from pSE280 or with addition of sodium chloride to the culture medium (data not shown), suggesting that overexpression of \textit{wzzB} from pSEC10 in noninduced growth conditions is already saturating. Similarly, the overexpression of \textit{fepE} resulted in an increase in the proportion of very long chain OPS (Fig. 2a,b). The empty plasmid did not have any impact on the OPS chain length (Fig. 2a).

Expression of \textit{S. Typhimurium} \textit{wzzB} in \textit{S. Paratyphi A} CVD 1902 and \textit{S. flexneri} 2a CVD 1208S

In order to test whether overexpression of \textit{S. Typhimurium} \textit{wzzB} could confer similar modal length changes among other bacteria that use the Wzx-/Wzy-dependent LPS synthesis pathway, pSEC10-\textit{wzzB} was transformed into \textit{S. Paratyphi A} CVD 1902, and into \textit{S. flexneri} CVD 1208S. The overexpression of \textit{S. Typhimurium} \textit{wzzB} in these two strains led to the production of OPS with a modal chain length distribution similar to that observed for \textit{S. Typhimurium} CVD 1925 (pSEC10-\textit{wzzB}) (Fig. 3). The OPS produced by \textit{S. Paratyphi A} CVD 1902 (pSEC10-\textit{wzzB}) shifted to a longer modal length (Fig. 3a) while for \textit{S. flexneri} CVD 1208S (pSEC10-\textit{wzzB}) a shift from short to very long OPS to a uniform high molecular weight species intermediate between the short and very long O chain length was observed (Fig. 3b). The empty plasmid did not induce any change in the LPS population compared to the parental strains (Fig. 3).

Densitometry analysis of the OPS produced in strains overexpressing \textit{S. Typhimurium} \textit{wzzB}

Overexpression of \textit{wzzB} induced a c. 10-fold increase in the proportion of synthesized long-chain OPS in \textit{S. Typhimurium}.
Typhimurium CVD 1925 (Fig. 4). While the total amount of OPS produced remained equal between S. Paratyphi A CVD 1902 (pSEC10-wzzB) and CVD 1208S (pSEC10-wzzB) and their respective parental strains S. Paratyphi A CVD 1902 and S. flexneri CVD 1208S, S. Typhimurium CVD 1925 (pSEC10-wzzB) had a significantly higher signal intensity than S. Typhimurium CVD 1925 (Fig. 4). Since all samples were normalized, the data suggest that S. Typhimurium CVD 1925 (pSEC10-wzzB) actually synthesizes more OPS than its parental strain.

Overexpression of wzz2 in P. aeruginosa PAO1 and in heterologous strains of the same species, P. aeruginosa IATS O6 and IATS O10

We applied the same strategy to control the OPS length in P. aeruginosa, another GNB that uses the Wzx-/Wzy-dependant pathway for LPS synthesis. Similar to the results found for S. Typhimurium CVD 1925, overexpression of P. aeruginosa wzz2 in P. aeruginosa strain PAO1 caused a significant increase in the proportion of long-chain OPS (Fig. 5). When wzz2 was overexpressed in P. aeruginosa strain IATS O10 a significant increase in long-chain LPS was balanced by a significant decrease in medium chain LPS (Fig. 5c) The overexpression of wzz2 in P. aeruginosa IATS O6 lead to a significant increase in the proportion of very long chain OPS (Fig. 5).

Discussion

As biological products, vaccines have moved steadily away from poorly defined and difficult to standardize preparations (e.g. heat or chemically inactivated whole-cell vaccines), towards well-defined products (e.g. subunit vaccines). Based on encouraging preclinical results, there is broad enthusiasm and intensive research efforts towards development of OPS-based vaccines for a
multitude of GNB pathogens (Svenson and Lindberg 1981; Watson et al. 1992; Cohen et al. 1997; Simon et al. 2011). Immunogenic and effective protein-polysaccharide glycoconjugate vaccines are among the most complex vaccines to design due to several contributing factors including variability in the saccharide hapten size and carrier protein, linkage site between the saccharide and protein carrier, and chemistries required to link the hapten and carrier protein (Bardotti et al. 2008; Stefanetti et al. 2014; Broker et al. 2016). Control over the polysaccharide hapten size is thus important towards the development of glycoconjugate vaccines. Production of well-defined and uniform lower molecular weight polysaccharide fragments for Neisseria meningitidis and Haemophilus influenzae type b (Hib) capsular polysaccharides has been accomplished by chemical or mechanical polysaccharide depolymerization, respectively, followed by size fractionation (Bardotti et al. 2008; Broker et al. 2016). Biochemical size fractionation has also been used for purified Shigella COPS, whereby a preferred immunogenic saccharide size population was identified (Robbins et al. 2009; Kubler-Kielb et al. 2010; Zhang et al. 2013).

S. Typhimurium OPS haptens of reduced size produced by enzymatic cleavage of S. Typhimurium COPS with a phage-associated endorhamnosidase were used as glycoconjugate haptens to establish the minimal immunogenic repeat number (Svenson and Lindberg 1981). Chemical synthesis approaches have also been utilized to produce bacterial polysaccharide haptens of uniform size and composition (Aguilar-Betancourt et al. 2008; Phalipon et al. 2009; Polonskaya et al. 2017). Manipulation of the OPS synthesis pathway represents an efficient and economical approach to achieve high yields of homogenous polysaccharides of a predetermined size, with clear advantages over the prior approaches.

The S. Typhimurium strain CVD 1925 produces predominantly short to medium molecular weight LPS with a characteristic laddering pattern under normal growth conditions (Fig. 2). Overexpression of the O antigen modal length regulator wzzB from a plasmid in this strain overcame this deficiency, resulting in the production of c. 10-fold higher levels of long-chain saccharide size. Overexpression of fepE, the very long O antigen modal length regulator, in this same strain also shifted the OPS

Figure 2 (a) Visualization of LPS produced by Salmonella Typhimurium CVD 1925 (lane 1), carrying the empty pSEC10 plasmid (lane 2), carrying pSEC10-wzzB (lane 3) and carrying pSEC10-fepE (lane 4). (b) Distribution of the signal intensity in lane 1 (S. Typhimurium CVD 1925, red), lane 3 (S. Typhimurium CVD 1925 [pSEC10-wzzB], green) and lane 4 (S. Typhimurium CVD 1925 [pSEC10-fepE], blue). (c) Proportion of each OPS population relative to the total signal intensity per lane for S. Typhimurium CVD 1925 (dark grey bars) and S. Typhimurium CVD 1925 (pSEC10-wzzB) (light grey bars). (Colour figure can be viewed at wileyonlinelibrary.com)

Figure 3 (a) Visualization of LPS produced by Salmonella Paratyphi A CVD 1902 (lane 1), S. Paratyphi A CVD 1902 (pSEC10) (lane 2) and S. Paratyphi A CVD 1902 (pSEC10-wzzB) (lane 3) and visualization of the signal intensity distribution and proportion of each OPS population in S. Paratyphi A CVD 1902 (red histogram, dark grey bars) and S. Paratyphi A CVD 1902 (pSEC10-wzzB) (green histogram, light grey bars). (b) Visualization of LPS produced by S. flexneri CVD 1208S (lane 1), S. flexneri CVD 1208S (pSEC10) (lane 2) and S. flexneri CVD 1208S (pSEC10-wzzB) (lane 3) and visualization of the signal intensity distribution and proportion of each OPS population in S. flexneri CVD 1208S (red histogram, dark grey bars) and S. flexneri CVD 1208S (pSEC10-wzzB) (green histogram, light grey bars). (Colour figure can be viewed at wileyonlinelibrary.com)
S. Paratyphi A
CVD 1902

(a)

S. flexneri
CVD 1208s

(b)

Proportion of each LPS population (%)

OPS length

0 20 40 60 80 100

Short Medium Long Very-long

Intensity (RLU)

wzzB

Proportion of each LPS population (%)

OPS length

0 20 40 60 80 100

Short Medium Long Very-long
population from predominantly short to very long. *S. Paratyphi A*, a serogroup A *Salmonella* that produces OPS that is structurally very similar to *S. Typhimurium* (Lindberg 1984), expresses almost entirely short-chain OPS (Boyd *et al*. 2014). We found that expression of wzzB from *S. Typhimurium* CVD 1925 in *S. Paratyphi A* CVD 1902 shifted the saccharide population to long length LPS with the same molecular weight as that produced by *S. Typhimurium* CVD 1925. *S. flexneri* 2a expresses two separate chromosomally- and plasmid-encoded wzz genes (e.g. wzzB and wzzAPHS-2 respectively) that specify either short or very long LPS types (Carter *et al*. 2009). High-level expression of *S. Typhimurium* CVD 1925 wzzB by *S. flexneri* CVD 1208S supplanted almost fully the action of the endogenously encoded *Shigella* Wzz proteins, producing a homogenous population of intermediate molecular weight LPS. It has been suggested that the higher expression level of plasmid-encoded OPS chain length regulators shifts the stoichiometry of the reaction and forces the system to use the recombinant Wzz protein instead of native Wzz proteins (Islam and Lam 2014). This might result in a competition between native Wzz proteins and WzzB for the engagement of Wzy and control of the O-polysaccharide length. This finding provides a precedent for shifting the saccharide size from both long and short towards an intermediate and uniform size. When this strategy was applied to *P. aeruginosa* we found comparable results whereby the overexpression of PAO1 wzz2 induced an increase in the modal length of the OPS populations in the three distinct strains. The overexpression of wzz2 in *P. aeruginosa* IATS O6, however, produced an O antigen population with a higher molecular weight observed by SDS-PAGE than that produced by *P. aeruginosa* PAO1 overexpressing wzz2. This discrepancy may be accounted for by differences in OPS structure and interaction with the Wzz proteins (Islam and Lam 2014) or differences in SDS-PAGE migration as a function of the overall saccharide charge, as has been noted for other *Pseudomonas* OPS (King *et al*. 2008).

The genetic approach described herein enables product uniformity and enhanced yield of polysaccharides of a defined size. Should these polysaccharides present the optimum size for conjugation and immunity against the targeted pathogen, this would obviate the need for additional sizing steps that can introduce extraneous costs to the production process. Conceivably, it could be used to generate improved OPS haptens for several important GNB pathogens that use the Wzx-/Wzy-dependant pathway (e.g. *Salmonella*, *Shigella*, *Pseudomonas*, *Yersinia*, *Campylobacter*, *Acinetobacter*, *Francisella*, *Burkholderia*, *Escherichia coli*) and is an important advance towards enabling efficient use of OPS molecules as haptens by providing an interesting alternative strategy to facilitate carbohydrate vaccine development. Our team has already designed a highly immunogenic and protective *S. Typhimurium* glycoconjugate vaccine using wzzB-controlled OPS antigen haptens, proof that this strategy is effective (Baliban *et al*. 2017). *Salmonella Typhimurium* overexpressing wzzB produced a single high molecular weight species of O-polysaccharide as measured by HPLC-SEC. In contrast, wild-type *Salmonella Typhimurium* produced a bimodal size distribution. COPS was purified from the wzzB overexpresser using Tangential Flow Filtration (TFF) but no additional sizing steps thereby making purification simple and economical. In terms of immunogenicity, we previously observed that short-chain OPS expressed by *S. Typhimurium* failed to induce significant antipolysaccharide antibody titres in the context of end-linkage to a protein carrier (unpublished results), whereas the long-chain form isolated from a *S. Typhimurium* strain overexpressing wzzB was highly immunogenic when linked with the identical chemistry. Others have also found that the long chain form of *S. Typhimurium*
OPS is optimally immunogenic, however, the very long chain form was a poor vaccine hapten when end-linked (Rondini et al. 2015). It has also been previously shown that the short-chain COPS from *S. dysenteriae* was more immunogenic than the long form when linked through the reducing end to a protein carrier (Robbins et al. 2009). One proposed mechanism accounting for this latter observation was that the higher polysaccharide substitution ratio on the protein permitted by conjugation of shorter chain oligosaccharides enabled increased molar ratios of nonreducing end units, that are the immunodominant epitopes for this polysaccharide (Pozsgay

Figure 5 (a) Visualization of LPS produced by wild-type *Pseudomonas aeruginosa* strains PAO1 (lane 1), IATS O6 (lane 4) and IATS O10 (lane 7), and the same strains carrying pUCP19 (lanes 2, 5 and 8 respectively) or pUCP19-wzz2 (lanes 3, 6 and 9 respectively). (b) Visualization of the signal intensity distribution for the wild-type (red) and the wzz2 overexpressing (green) PAO1, IATS O6 and IATS O10 strains. (c) Proportion of each OPS population relative to the total signal intensity per lane for wild-type (dark grey) and wzz2 overexpressing (light grey) strains of PAO1 (left), IATS O6 (middle) and IATS O10 (right). [Colour figure can be viewed at wileyonlinelibrary.com]
et al. 2007). By comparison, for polysaccharides for which the central repeat units are immunodominant (e.g. S. Typhimurium OPS), the long-chain polysaccharide form constitutes the desired hapten.

Various models attempt to explain the way wzz regulates OPS chain length (Islam and Lam 2014). It is likely that deeper understanding of that pathway could lead to a tunable method for controlling the synthesis of saccharides of an optimum size through overexpression of different wzz genes. Deleting the chromosomal wzz genes in the desired GNB or overexpressing the homologous wzz gene of a given GNB could also be explored to optimize the strategy described herein and maybe obtain even higher OPS yields of a desired size. The findings described in this study provide a proof of concept for applications whereby the desired saccharide population is not efficiently produced (e.g. glycoconjugate vaccine production) and work performed in our laboratory demonstrates that this strategy can be effectively used to improve glycoconjugate vaccine production.

Acknowledgements

We thank Dr. Joseph Lam for the kind gift of the P. aeruginosa IATS O6 and O10 strains. We thank Dr. Amanda Oglesby-Sherrouse for the kind gift of pUCP19. Funding was from a Wellcome Trust Strategic Translation Award (MML PI).

Conflicts of Interest

Drs. Tennant, Simon and Levine have a patent pending that includes the use of wzz to improve polysaccharide purification for conjugate vaccines “Compositions and Methods for Producing Bacterial Conjugate Vaccines, PCT Patent Application Serial Number PCT/US2016/027325.” The authors declare no other conflicts of interest.

References

Aguilar-Betancourt, A., Gonzalez-Delgado, C.A., Cinza-Estevez, Z., Martinez-Cabrera, J., Veliz-Rios, G., Aleman-Zaldivar, R., Alonso-Martinez, M.I., Lago-Banos, M. et al. (2008) Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults. *Hum Vaccin* 4, 54–59.

Al-Dujaili, A.H. and Harris, D.M. (1974) Evaluation of commercially available antisera for serotyping of *Pseudomonas aeruginosa*. *J Clin Pathol* 27, 569–571.

Avci, F.Y., Li, X., Tsuji, M. and Kasper, D.L. (2011) A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. *Nat Med* 17, 1602–1609.

Baliban, S.M., Yang, M., Ramachandran, G., Curtis, B., Shridhar, S., Lauffer, R.S., Wang, J.Y., Van Druff, J. et al. (2017) Development of a glycoconjugate vaccine to prevent invasive *Salmonella* Typhimurium infections in sub-Saharan Africa. *PLoS Negl Trop Dis* 11, e0005493.

Bardotti, A., Averani, G., Berti, F., Berti, S., Carinci, V., D’Ascenzi, S., Fabbri, B., Giannini, S. et al. (2008) Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. *Vaccine* 26, 2284–2296.

Boyd, M.A., Tennant, S.M., Saague, V.A., Simon, R., Muhsen, K., Ramachandran, G., Cross, A.S., Galen, J.E. et al. (2014) Serum bactericidal assays to evaluate typhoidal and nontyphoidal *Salmonella* vaccines. *Clin Vaccine Immunol* 21, 712–721.

Bravo, D., Silva, C., Carter, J.A., Hoare, A., Alvarez, S.A., Blondel, C.J., Zaldivar, M., Valvano, M.A. et al. (2008) Growth-phase regulation of lipopolysaccharide O-antigen chain length influences serum resistance in serovars of *Salmonella*. *J Med Microbiol* 57, 938–946.

Broker, M., Berti, F. and Costantino, P. (2016) Factors contributing to the immunogeneity of meningococcal conjugate vaccines. *Hum Vaccin Immunother* 12, 1808–1824.

Campbell, W.N., Hendrix, E., Cryz, S. Jr and Cross, A.S. (1996) Immunogenicity of a 24-valent *Klebsiella* capsular polysaccharide vaccine and an eight-valent *Pseudomonas* O-polysaccharide conjugate vaccine administered to victims of acute trauma. *Clin Infect Dis* 23, 179–181.

Carter, J.A., Blondel, C.J., Zaldivar, M., Alvarez, S.A., Marolda, C.L., Valvano, M.A. and Contreras, I. (2007) O-antigen modal chain length in *Shigella flexneri* 2a is growth-regulated through RapH-mediated transcriptional control of the wzy gene. *Microbiology* 153, 3499–3507.

Carter, J.A., Jimenez, J.C., Zaldivar, M., Alvarez, S.A., Marolda, C.L., Valvano, M.A. and Contreras, I. (2009) The cellular level of O-antigen polymerase Wzy determines chain length regulation by WzzB and WzzpHS-2 in *Shigella flexneri* 2a. *Microbiology* 155, 3260–3269.

Cohen, D., Ashkenazi, S., Green, M.S., Gdalevich, M., Robin, G., Slepon, R., Yavzori, M., Orr, N. et al. (1997) Double-blind vaccine-controlled randomised efficacy trial of an investigational *Shigella sonnei* conjugate vaccine in young adults. *Lancet* 349, 155–159.

Daniels, C., Griffiths, C., Cowles, B. and Lam, J.S. (2002) *Pseudomonas aeruginosa* O-antigen chain length is determined before ligation to lipid A core. *Environ Microbiol* 4, 883–897.

Erridge, C., Bennett-Guerrero, E. and Poxtom, I.R. (2002) Structure and function of lipopolysaccharides. *Microbes Infect* 4, 837–851.

Finco, O. and Rappuoli, R. (2014) Designing vaccines for the twenty-first century society. *Front Immunol* 5, 12.

Greenfield, L.K. and Whitfield, C. (2012) Synthesis of lipopolysaccharide O-antigens by ABC transporter-dependent pathways. *Carbohydr Res* 356, 12–24.
Hitchcock, P.J. and Brown, T.M. (1983) Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol 154, 269–277.

Holloway, B.W. (1969) Genetics of Pseudomonas. Bacteriol Rev 33, 419–443.

Islam, S.T. and Lam, J.S. (2014) Synthesis of bacterial polysaccharides via the Wzx/Wey-dependent pathway. Can J Microbiol 60, 697–716.

King, J.D., Mulrooney, E.F., Vinogradov, E., Kneidinger, B., Mead, K. and Lam, J.S. (2008) fnIA from Pseudomonas aeruginosa O12 and wbuX from Escherichia coli O145 encode membrane-associated proteins and are required for expression of 2,6-dideoxy-2-acetamido-L-galactose in lipopolysaccharide O antigen. J Bacteriol 190, 1671–1679.

Konadu, E.Y., Lin, F.Y., Ho, V.A., Thuy, N.T., Van Bay, P., Thanh, T.C., Khiem, H.B., Trach, D.D. et al. (2000) Phase 1 and phase 2 studies of Salmonella enterica serovar Paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 68, 1529–1534.

Kotloff, K.L., Simon, J.K., Pasetti, M.F., Sztein, M.B., Wooden, S.L., Livio, S., Nataro, J.P., Blackwelder, W.C. et al. (2007) Safety and immunogenicity of CVD 1208S, a live, oral Escherichia-Pseudomonas shuttle vectors derived from pUC18/19. Gene 345, 1600–1608.

Lam, J.S., MacDonald, L.A., Lam, M.Y., Duchesne, L.G. and Southam, G.G. (1987) Production and characterization of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa. Infect Immun 55, 1051–1057.

Lindberg, A.A.L.M. (1984) Serology of Salmonella, Vol. 15, pp. 1–64. London: Academic Press. (Bergman T ed.).

Murray, G.L., Attridge, S.R. and Morona, R. (2003) Regulation of Salmonella Typhimurium lipopolysaccharide O antigen chain length is required for virulence; identification of FepE as a second Wzz. Mol Microbiol 47, 1395–1406.

Philapin, A., Tanguy, M., Grandjean, C., Guerreiro, C., Belot, F., Cohen, D., Sansonetti, P.J. and Mulard, L.A. (2009) A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J Immunol 182, 2241–2247.

Podschun, R. and Ullmann, U. (1998) Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 11, 589–603.

Polonskaya, Z., Deng, S., Sarkar, A., Kain, L., Comellas-Aragones, M., McKay, C.S., Kaczanowska, K., Holt, M. et al. (2017) T cells control the generation of nanomolar-affinity anti-glycan antibodies. J Clin Invest 127, 1491–1504.

Pozsgay, V., Kubler-Kielb, J., Schneerson, R. and Robbins, J.B. (2007) Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. Proc Natl Acad Sci USA 104, 14478–14482.

Robbins, J.B., Kubler-Kielb, J., Vinogradov, E., Mocca, C., Pozsgay, V., Shiloach, J. and Schneerson, R. (2009) Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates. Proc Natl Acad Sci USA 106, 7974–7978.

Rondini, S., Micoli, F., Lanzilao, L., Gavini, M., Alfini, R., Brandt, C., Clare, S., Mastroeni, P. et al. (2015) Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium. Infect Immun 83, 996–1007.

Schweizer, H.P. (1991) Escherichia-Pseudomonas shuttle vectors in rabbits and mice against aerosolized B. anthracis protective antigen confers protection against B. anthracis. Infect Immun 75, 1827–1834.

Svenson, S.B. and Lindberg, A.A. (1981) Artificial Salmonella vaccines: Salmonella Typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice. Infect Immun 32, 490–496.

Tennant, S.M., Wang, J.Y., Galen, J.E., Simon, R., Pasetti, M.F., Gat, O. and Levine, M.M. (2011) Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infect Immun 79, 4175–4185.

Watson, D.C., Robbins, J.B. and Szu, S.C. (1992) Protection of mice against Salmonella Typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun 60, 4679–4686.

Wattiau, P., Boland, C. and Bertrand, S. (2011) Methodologies for Salmonella enterica subsp. enterica subtyping: gold standards and alternatives. Appl Environ Microbiol 77, 7877–7885.

Zhang, F., Lu, Y.J. and Malley, R. (2013) Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity. Proc Natl Acad Sci USA 110, 13564–13569.